The global pharmerging market size is expected to Worth $2261.9 Billion By 2026 and is expected to grow at a CAGR of 18.7% over the forecast period 2019 to 2026.
The report analyzes and forecasts the Pharmerging market at global and regional levels. The market has been forecast based on volume (Tons) and value (US$ Mn) from 2019 to 2026. The study includes drivers and restraints of the global market. It covers the impact of these drivers and restraints on the demand during the forecast period. The report also highlights opportunities in the market at the global level. For the region and all segments, the sales, revenue and their market share, growth rate are key research objects; we can research the manufacturers' sales, price, revenue, cost and gross profit and their changes. What's more, we will display the main consumers, raw material manufacturers, distributors, etc.
This report first introduces the background of Pharmerging, including the definition, classification, application, industrial chain structure, industry overview, national policy and planning analysis of the industry, and the latest dynamic analysis. With regard to production bases and technologies, the research in this report covers the production time, base distribution, technical parameters, research and development trends, technology sources, and sources of raw materials of major Pharmerging companies.
Regarding the analysis of the industry chain, the research of this report covers the raw materials and equipment of Pharmerging upstream, downstream customers, marketing channels, industry development trends and investment strategy recommendations. The more specific analysis also includes the main application areas of Pharmerging and consumption, major regions and consumption, major global producers, distributors, raw material suppliers, equipment providers and their contact information, industry chain relationship analysis.
The report comprises a detailed value chain analysis, which provides a comprehensive view of the global Pharmerging market. The Porter’s Five Forces model has also been included to help understand the competitive landscape of the market. The study encompasses market attractiveness analysis, wherein various applications have been benchmarked based on their market size, growth rate, and general attractiveness.
The study provides a decisive view of the Pharmerging market by segmenting it in terms of form and application. The segment has been analyzed based on the present and future trends. Regional segmentation includes the current and projected demand in North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.
The report provides size (in terms of volume and value) of Pharmerging market for the base year 2018 and the forecast between 2019 and 2026. Market numbers have been estimated based on form and application. Market size and forecast for each application segment have been provided for the global and regional market.
Companies Mentioned in the Research Report
The report profiles key manufacturers in the pharmerging market based on various attributes such as company details, SWOT analysis, strategic overview, financials, and business overview. Major players profiled in this report include Abbott Laboratories, Koninklijke Philips N.V., F. Hoffmann-La Roche Ltd., Merck & Co., Inc., Novartis AG, Johnson & Johnson, Teva Pharmaceutical Industries Ltd., AstraZeneca, GlaxoSmithKline plc., LUPIN, Tata Consultancy Services Limited, Sun Pharmaceutical Industries Ltd., Huadong Medicine Co., Ltd., etc.
The global pharmerging Market has been segmented as follows:
By Product Type
By Indications
By Distribution Channel
By Region
Research Methodology:
In-depth interviews and discussions were conducted with several key market participants and opinion leaders to compile the research report.
Primary research represents a bulk of research efforts, supplemented by extensive secondary research. Annual reports, press releases, and relevant documents of key players operating in various application areas have been reviewed for competition analysis and market understanding.
Secondary research also includes recent trends, technical writing, Internet sources, and statistical data from government websites, trade associations, and agencies. These have proved to be reliable, effective, and successful approaches for obtaining precise market data, capturing market participants’ insights, and recognizing business opportunities.
The study objectives of this report are:
Section 01 Preface
1.1. Report Scope and Market Segmentation
1.2. Research Highlights
Section 02 Assumptions and Research Methodology
2.1. Assumptions and Acronyms Used
2.3. Research Methodology
Section 03 Executive Summary
3.1. Global Pharmerging Market Snapshot
Section 04 Market Overview
4.1. Product Overview
4.2. Key Industry Developments
Section 05 Market Dynamics
5.1. Opportunity Analysis
5.2. Drivers and Restraints Snapshot Analysis
5.3. Drivers
5.3.1. Continuous Research and Development
5.3.2. Increasing Government Expenditure on Healthcare
5.3.3. Rising non-communicable diseases (NCDs)
5.3.4. Free trade agreement
5.3.5. Growing income
5.3.6. Aging population and increasing life expectancy
5.4. Restraints
5.4.1. Economic challenges in Africa
5.4.2. Weak or ambiguous patent laws
5.4.3. Growing medical tourism
5.4.4. Partnerships and acquisition of local players by MNCs
5.5. Porter’s Analysis
5.6. Value Chain Analysis (Medical Devices)
5.7. Value Chain Analysis (Pharmaceuticals)
5.8. Mergers and Acquisitions Landscape
5.9. Reimbursement Scenario
5.10. Pharmerging Market Outlook
Section 06 Global Pharmerging Market Analysis, by Product Type
6.1. Key Findings
6.2. Introduction
6.3. Market Forecast by Product Type
6.3.1. Pharmaceuticals
6.3.1.1. Branded Prescription Drugs
6.3.1.2. Generic Drugs
6.3.1.2.1. Branded Generic
6.3.1.2.2. Unbranded Generic
6.3.1.3. OTC Drugs
6.3.2. Healthcare
6.3.2.1. Medical Devices
6.3.2.2. In Vitro Diagnostic
6.3.2.3. Others (IT and record management)
6.4. Global Pharmerging Market Attractiveness Analysis, by Product Type
6.3. Key Trends
Section 07 Global Pharmerging Market Analysis, by Indications
7.1. Key Findings
7.2. Introduction
7.3. Market Forecast by Indications
7.3.1. Lifestyle Diseases
7.3.2. Cancers & Autoimmune diseases
7.3.3. Infectious diseases
7.3.4. Others
7.4. Global Pharmerging Market Attractiveness Analysis, by Indications
Section 08 Global Pharmerging Market Analysis, by Distribution Channel
8.1. Key Findings
8.2. Introduction
8.3. Market Forecast by Distribution Channel
8.3.1. Hospitals
8.3.2. Clinics
8.3.3. Retail Pharmacies
8.3.4. E-commerce
8.3.5. Drug Stores
8.4. Global Pharmerging Market Attractiveness Analysis, by Distribution Channel
8.5. Key Trends
Section 09 Global Pharmerging Market Analysis, by Economic Growth Levels
9.1. Key Findings
9.2. Introduction
9.3. Market Forecast by Economic Growth Levels
9.3.1. Tier-1
9.3.2. Tier-2
9.3.3. Tier-3
9.4. Global Pharmerging Market Attractiveness Analysis, by Economic Growth Levels
Section 10 Global Pharmerging Market Analysis, by Region
10.1. Global Market Scenario, by Country
10.2. Global Pharmerging Market Value Share Analysis and Market Attractiveness Analysis, by Region
10.2.1. Market Forecast by Region
10.2.2. Latin America
10.2.3. Asia Pacific
10.2.4. Europe
10.2.5. Middle East & Africa
Section 11 Latin America Pharmerging Market Analysis
11.1. Key Findings
11.2. Market Overview
11.3. Latin America Pharmerging Market Value Share Analysis, by Country
11.4. Latin America Pharmerging Market Forecast, by Country
11.5. Latin America Pharmerging Market Value Share Analysis, by Product Type
11.6. Latin America Pharmerging Market Forecast, by Product Type
11.7. Latin America Pharmerging Market Value Share Analysis, by Indications
11.8. Latin America Pharmerging Market Forecast, by Indications
11.9. Latin America Pharmerging Market Value Share Analysis, by Distribution Channel
11.10. Latin America Pharmerging Market Forecast, by Distribution Channel
11.11. Latin America Pharmerging Market Attractiveness Analysis
Section 12 Asia Pacific Pharmerging Market Analysis
12.1. Key Findings
12.2. Market Overview
12.3. Asia Pacific Pharmerging Market Value Share Analysis, by Country
12.4. Asia Pacific Pharmerging Market Forecast, by Country
12.5. Asia Pacific Pharmerging Market Value Share Analysis, by Product Type
12.6. Asia Pacific Pharmerging Market Forecast, by Product Type
12.7. Asia Pacific Pharmerging Market Value Share Analysis, by Indications
12.8. Asia Pacific Pharmerging Market Forecast, by Indications
12.9. Asia Pacific Pharmerging Market Value Share Analysis, by Distribution Channel
12.10. Asia Pacific Pharmerging Market Forecast, by Distribution Channel
12.11. Asia Pacific Pharmerging Market Attractiveness Analysis
Section 13 Europe Pharmerging Market Analysis
13.1. Key Findings
13.2. Market Overview
13.3. Europe Pharmerging Market Value Share Analysis, by Country
13.4. Europe Pharmerging Market Forecast, by Country
13.5. Europe Pharmerging Market Value Share Analysis, by Product Type
13.6. Europe Pharmerging Market Forecast, by Product Type
13.7. Europe Pharmerging Market Value Share Analysis, by Indications
13.8. Europe Pharmerging Market Forecast, by Indications
13.9. Europe Pharmerging Market Value Share Analysis, by Distribution Channel
13.10. Europe Pharmerging Market Forecast, by Distribution Channel
13.11. Europe Pharmerging Market Attractiveness Analysis
Section 14 Middle East & Africa Pharmerging Market Analysis
14.1. Key Findings
14.2. Market Overview
14.3. Middle East & Africa Pharmerging Market Value Share Analysis, by Country
14.4. Middle East & Africa Pharmerging Market Forecast, by Country
14.5. Middle East & Africa Pharmerging Market Value Share Analysis, by Product Type
14.6. Middle East & Africa Pharmerging Market Forecast, by Product Type
14.7. Middle East & Africa Pharmerging Market Value Share Analysis, by Indications
14.8. Middle East & Africa Pharmerging Market Forecast, by Indications
14.9. Middle East & Africa Pharmerging Market Value Share Analysis, by Distribution Channel
14.10. Middle East & Africa Pharmerging Market Forecast, by Distribution Channel
14.11. Middle East & Africa Pharmerging Market Attractiveness Analysis
Section 15 Competition Landscape
15.1. Competition Matrix
15.2. Pharmerging Market Share Analysis by Company, 2018
15.3. Company Profiles
15.3.1 Abbott Laboratories
15.3.1.1 Financial Overview
15.3.1.2. Product Portfolio
15.3.1.3. Business Strategies
15.3.1.4. Recent Developments
15.3.2 Koninklijke Philips N.V.
15.3.2.1 Financial Overview
15.3.2.2. Product Portfolio
15.3.2.3. Business Strategies
15.3.2.4. Recent Developments
15.3.3 F. Hoffmann-La Roche Ltd.
15.3.3.1 Financial Overview
15.3.3.2. Product Portfolio
15.3.3.3. Business Strategies
15.3.3.4. Recent Developments
15.3.4. Merck & Co., Inc.
15.3.4.1 Financial Overview
15.3.4.2. Product Portfolio
15.3.4.3. Business Strategies
15.3.4.4. Recent Developments
15.3.5 Novartis AG
15.3.5.1 Financial Overview
15.3.5.2. Product Portfolio
15.3.5.3. Business Strategies
15.3.5.4. Recent Developments
15.3.6 Johnson & Johnson
15.3.6.1 Financial Overview
15.3.6.2. Product Portfolio
15.3.6.3. Business Strategies
15.3.6.4. Recent Developments
15.3.7 Teva Pharmaceutical Industries Ltd.
15.3.7.1 Financial Overview
15.3.7.2. Product Portfolio
15.3.7.3. Business Strategies
15.3.7.4. Recent Developments
15.3.8. AstraZeneca
15.3.8.1 Financial Overview
15.3.8.2. Product Portfolio
15.3.8.3. Business Strategies
15.3.8.4. Recent Developments
15.3.9. GlaxoSmithKline plc.
15.3.9.1 Financial Overview
15.3.9.2. Product Portfolio
15.3.9.3. Business Strategies
15.3.9.4. Recent Developments
15.3.10. LUPIN
15.3.10.1 Financial Overview
15.3.10.2. Product Portfolio
15.3.10.3. Business Strategies
15.3.10.4. Recent Developments
15.3.11. Tata Consultancy Services Limited
15.3.11.1 Financial Overview
15.3.11.2. Product Portfolio
15.3.11.3. Business Strategies
15.3.11.4. Recent Developments
15.3.12. Sun Pharmaceutical Industries Ltd
15.3.12.1 Financial Overview
15.3.12.2. Product Portfolio
15.3.12.3. Business Strategies
15.3.12.4. Recent Developments
15.3.13. Huadong Medicine Co., Ltd
15.3.13.1 Financial Overview
15.3.13.2. Product Portfolio
15.3.13.3. Business Strategies
15.3.13.4. Recent Developments
Cross-segment Market Size and Analysis for
Mentioned Segments
Additional Company Profiles (Upto 5 With No Cost)
Additional Countries (Apart From Mentioned Countries)
Country/Region-specific Report
Go To Market Strategy
Region Specific Market DynamicsRegion Level Market Share Import Export AnalysisProduction AnalysisOthers